Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000732507 | SCV000860472 | uncertain significance | not provided | 2018-03-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001294512 | SCV001483392 | uncertain significance | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2; Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B2; Autosomal recessive limb-girdle muscular dystrophy type 2N | 2023-05-15 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on POMT2 protein function. This sequence change replaces isoleucine, which is neutral and non-polar, with asparagine, which is neutral and polar, at codon 198 of the POMT2 protein (p.Ile198Asn). This variant is present in population databases (rs267606972, gnomAD 0.0009%). This missense change has been observed in individual(s) with POMT2-related conditions (PMID: 17878207). ClinVar contains an entry for this variant (Variation ID: 3227). |
OMIM | RCV000003383 | SCV000023541 | pathogenic | Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2 | 2007-10-01 | no assertion criteria provided | literature only |